CVRX Earnings Prediction
The chart below shows how CVRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CVRX sees a -3.36% change in stock price 10 days leading up to the earnings, and a +6.24% change 10 days following the report. On the earnings day itself, the stock moves by +1.31%. This data can give you a slight idea of what to expect for the next quarter's release.
CVRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
15.34M
35.71%
14.72%
Gross Margin
83.24%
-1.83%
0.06%
Operating Margin
-66.97%
-21.64%
-31.16%
Net Margin
-69.42%
-14.35%
-29.13%
EPS
-0.43
-2.27%
-24.56%
No Data Available
CVRX Earnings Analysis
CVRx Inc Corporation (CVRX.O) Earnings Conference Call
Positive
Q4 Revenue Surge: Total revenue for Q4 2024 reached $15.3 million, a 36% increase compared to Q4 2023, driven by a 41% growth in U.S. Heart Failure revenue.
Active Implanting Centers Growth: The number of active implanting centers increased to 223 by the end of 2024, up from 178 at the end of 2023, reflecting successful expansion efforts.
Q4 Gross Profit Increase: Gross profit for Q4 2024 was $12.8 million, representing an increase of $3.2 million compared to the same period last year, with a gross margin of 83%.
Barostim Therapy Access Improvement: The implementation of new Category I CPT codes for Barostim therapy is expected to enhance access and reduce prior authorization denials, facilitating broader adoption.
Revenue Projections for 2025: The company anticipates total revenue for 2025 to be between $63 million and $65 million, indicating strong growth expectations based on current market strategies.
Negative
European Revenue Decline: Total revenue generated in Europe was $1,000,000 for the fourth quarter of 2024, a decrease from 52 revenue units in the fourth quarter of 2023 to 41 in the fourth quarter of 2024.
Gross Margin Decline: Gross margin for the fourth quarter was 83%, down from 85% for the same period last year, indicating a decline in profitability.
R&D Expense Increase: Research and development expenses for the fourth quarter were $2,800,000, reflecting a 25% increase compared to the same period last year, indicating rising costs without corresponding revenue growth.
SG&A Expense Increase: SG&A expenses for the fourth quarter were $20,200,000, representing a 19% increase compared to the same period last year, driven by increased compensation expenses and indicating higher operational costs.
Net Loss Comparison: Net loss was $10,700,000 or $0.43 per share for the three months ended 12/31/2024, compared to a net loss of $9,200,000 or $0.44 per share for the same period last year, reflecting worsening financial performance.
CVRX FAQs
How does CVRX typically perform around its earnings report dates?
Is CVRx Inc (CVRX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CVRX Earning Call Sentiment
Earnings call transcript: CVRx Q4 2024 shows revenue growth, stock dips
CVRX.O
-1.14%Positive
The earnings call presents a mixed picture: strong revenue growth and positive reimbursement changes are offset by ongoing financial losses and operational risks. The Q&A reveals management's focus on expanding market penetration and addressing awareness issues, but also highlights uncertainties in cash burn and target account strategies. The issuance of new shares and stable gross margins suggest financial stability, but the lack of clear guidance on certain metrics tempers enthusiasm. Given these factors, a neutral stock price movement is expected over the next two weeks.
